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(57) ABSTRACT 
Amethod for treating ischemia by administering deltorphins 
to a mammal. Deltorphin I SEQ ID NO:1, delntorphin II 
SEQ ID NO:2 or combinations of deltorphins I SEQ ID 
NO:1 and II SEQ ID NO:2 may be administered. A deltor 
phin concentration of about 0.5—20 mg/kg body Weight, or 
alternatively a loWer concentration of about 1—1000 tag/kg 
body Weight of the mammal in a physiologically acceptable 
formulation is administered up to four hours after an 
ischemic episode. Deltorphins may also be administered 
prior to or concurrently With onset of ischemia. Cerebral or 
spinal cord ischemia or ischemic heart disease may be 
treated using the method of the invention. 
25 Claims, No Drawings 
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METHOD FOR TREATING ISCHEMIA 
This application is a continuation of U. S. application 
Ser. No. 09/302,820, ?led April 30, 1999 noW abondoned, 
Which claims the bene?t of U. S. provisional application Ser. 
No. 60/083,866, ?led May 1, 1998. 
FIELD OF THE INVENTION 
The invention relates to the use of deltorphins to treat 
cerebral ischemia and ischemic heart disease. 
BACKGROUND 
Tissues deprived of blood and oxygen undergo ischemic 
necrosis or infarction With possible irreversible organ dam 
age. Cerebral ischemia results from decreased blood and 
oxygen ?oW implicating one or more of the blood vessels of 
the brain. In cerebral ischemia, the individual suffers a stroke 
With sudden development of a focal neurologic de?cit and, 
in most cases, some degree of brain damage. The decreased 
blood How may be due to, for example, an occlusion such as 
a thrombus or embolus, vessel rupture, sudden fall in blood 
pressure, change in the vessel lumen diameter due to 
atherosclerosis, trauma, aneurysm, developmental 
malformation, altered permeability of the vessel Wall or 
increased viscosity or other quality of the blood. Decreased 
blood How may also be due to failure of the systemic 
circulation and severe prolonged hypotension. Ischemic 
necrosis of the spinal cord may result in sensory or motor 
symptoms or both that can be referred to cervical, thoracic 
or lumbar levels of the spine. Ischemic heart disease results 
from an imbalance betWeen myocardial oxygen supply and 
demand. In ischemic heart disease, the individual suffers 
angina pectoris, acute myocardial infarction or sudden 
death. The imbalance may be caused by, for example, 
atherosclerotic obstruction of one or more large coronary 
arteries, nonatheromatous coronary obstructive lesions such 
as embolism, coronary ostial stenosis associated With luetic 
aortitis, coronary artery spasm, congenital abnormalities of 
the coronary circulation, increased myocardial oxygen 
demands exceeding the normal supply capabilities as in 
severe myocardial hypertrophy, reduction in the oxygen 
carrying capacity of the blood such as in anemia, or as a 
consequence of inadequate cardiac perfusion pressure due to 
hypotension from any cause. 
Current treatments for ischemia encompass behavioral 
changes, drug therapy, and/or surgical intervention. Drugs 
are frequently preferred before resorting to invasive proce 
dures and to provide more immediate relief than long-term 
behavioral changes. Thus, there is a need for a therapeutic 
agent Which can be useful in treating or preventing ischemia. 
SUMMARY OF THE INVENTION 
The present invention ?lls this need by providing a 
method of treating ischemia in a mammal comprised of 
administering a pharmaceutically effective amount of a 
deltorphin to said mammal. The ischemic tissue may be 
brain, spinal cord or heart. 
The present invention is also directed to a method of 
reducing the effect of an ischemic episode comprised of 
administering a pharmaceutically effective amount of a 
deltorphin to said mammal. 
The present invention is also directed to a method of 
treating cerebral or spinal cord ischemia or ischemic heart 
disease in a mammal comprised of administering a pharma 
ceutically effective amount of a deltorphin to said mammal. 
Preferably, the deltorphin is administered in a pharma 
ceutical composition at a dosage in the range of about 0.5 
mg/kg body Weight to about 20 mg/kg body Weight, or 
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alternatively loWer doses in the range of about 1 pig/kg body 
Weight to about 1000 pig/kg body Weight of the mammal. 
Preferably, the mammal is a human. 
DETAILED DESCRIPTION 
Deltorphins are endogenous linear heptapeptides isolated 
from skin extracts of the South American frog Phyllomea'usa 
bicolor. These may be further divided into deltorphin I SEQ 
ID NO:1 and deltorphin II SEQ ID NO:2 depending on their 
amino acid sequence. Deltorphin I SEQ ID NO:1 has the 
amino acid sequence Tyr-Ala-Phe-Asp-Val-Val-Gly-NH2 
With alanine as either the L- or D- isomer. Deltorphin II SEQ 
ID NO:2 has the amino acid sequence Tyr-Ala-Phe-Glu-Val 
Val-Gly-NH2 With alanine as either the L- or D-isomer. 
Either deltorphin I SEQ ID NO:1, deltorphin II SEQ ID 
NO:2 or a combination of deltorphin I SEQ ID NO:1 and II 
SEQ ID NO:2 may be used in the invention. Deltorphins 
may be obtained from frog skin extracts or may be synthe 
siZed using a commercial peptide synthesiZer such the type 
available from Applied Biosystems. 
Deltorphins can be administered to ameliorate or inhibit 
damage caused by a stroke. A stroke is the acute neurologic 
injury caused by one of several pathologic processes involv 
ing the blood vessels of the brain. The pathologic process 
may be intrinsic to the vessel itself such as in 
arteriosclerosis, or may originate from a remote location 
such as an embolus, or may result from decreased perfusion 
or increased blood viscosity With inadequate cerebral blood 
?oW, or may result from the rupture of a vessel in the 
subarachnoid space or intracerebral tissue. 
The main causes of ischemic stroke are thrombosis, 
vasoconstriction and embolism. Diagnosis of a stroke can be 
readily made by one of ordinary skill in the art. Signs of 
stroke include paralysis, slurred speech, general confusion, 
impairment of gait, cortical sensory loss over toes, foot and 
leg and urinary incontinence, to name just a feW. The 
diagnosis can be con?rmed by cerebral angiography and by 
a computed axial tomography (CT) scan of the brain. 
If a stroke occurs, deltorphins can be administered to limit 
injury to the brain. The ideal mode of administration is by 
intraperitoneal (i.p.) or intravenous (iv) injection at a dose 
of about 0.5—20 mg/kg, or alternatively of about 1—1000 
pig/kg. Deltorphins can also be administered by subcutane 
ous or intraarterial injection into the carotid artery, or by 
direct injection into the brain, e.g, intracerebroventricular 
injection for dispersion into other areas. 
Very often a stroke is caused by a cerebral embolism, the 
likelihood of Which can frequently be predicted. In these 
cases, the deltorphin can be administered prophylactically to 
prevent or lessen the amount of brain tissue injured during 
such an event. Many types of heart disease including cardiac 
arrhythmias or diseases due to cardiac structural abnormali 
ties may produce cerebral emboli. Atrial ?brillation from 
any cause, including rheumatic valvular disease, may result 
in emboli being produced Which can migrate into the arteries 
of the brain. Emboli formation and migration can occur as 
a result of arteriosclerotic cardiovascular disease and myo 
cardial infarction. Emboli formation is also a de?nite risk for 
intracardiac surgery and prosthetic valve replacement. Heart 
bypass surgery and angioplasty can result in the formation of 
microemboli Which can migrate into the arteries of the brain 
and cause a series of occlusions in a number of arteries, 
resulting in mental impairment. Cerebral embolism is also 
the principal complication in the transplant of arti?cial 
hearts. Furthermore, the overall risk of stroke after any type 
of general surgery is 0.2 to 1 percent. The vegetations of 
acute and subacute bacterial endocarditis can give rise to 
emboli Which can occlude a major intracranial artery. Thus, 
When these disease states or surgical procedures are planned 
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or are happening, deltorphins can be administered to prevent 
brain damage due to any resultant emboli and stroke. 
Deltorphins can be administered to ameliorate or prevent 
ischemic necrosis of the spinal cord. The ischemia may be 
caused by an endarteritis of surface arteries leading to 
thrombosis. Atherosclerotic thrombosis of the aorta or dis 
secting aortic aneurysms may cause infarction of the spinal 
cord (myelomalacia) by occluding nutrient arteries at 
cervical, thoracic or lumbar levels, as can paralysis during 
cardiac surgery requiring clamping of the aorta for more 
than 30 minutes and aortic arteriography. Infarctive or 
hemorrhagic vascular lesions of the spinal cord 
(hematomyelia) may result in the sudden onset of symptoms 
referable to sensory or motor or both spinal tract lesions. 
Deltorphins can also be administered to ameliorate or 
inhibit damage caused by ischemic heart disease. Ischemic 
heart disease is a general term for a spectrum of diseases of 
diverse etiology caused by an imbalance betWeen oxygen 
supply and demand. The usual cause of the imbalance is 
atherosclerotic obstruction of large coronary arteries, lead 
ing to an absolute decrease in coronary artery blood ?oW. An 
imbalance may also result from nonatheromatous coronary 
obstructive lesions such as embolism, coronary ostial steno 
sis associated With luetic aortitis, coronary artery spasm, or 
very uncommonly an arteritis of the coronary vessels. The 
imbalance may also be due to congenital abnormalities of 
the coronary circulation, an increase in myocardial oxygen 
demands exceeding the supply capabilities in a normal 
coronary circulation, a diminished oxygen-carrying capacity 
of the blood such as in anemia or in the presence of 
carboxyhemoglobin (e. g., due to cigarette or cigar smoking), 
or as a consequence of inadequate perfusion pressure due to 
hypotension. When ischemic events are transient, they may 
be associated With angina pectoris; if prolonged, they can 
lead to myocardial necrosis and scarring With or Without the 
clinical picture of acute myocardial infarction. 
Ischemic heart disease may be readily diagnosed by one 
skilled in the art. There may be predictive changes in the 
electrocardiogram, since ischemia alters electrical properties 
of the heart. Such changes include inversion of the T Wave 
and displacement of the ST segment. Another important 
consequence of myocardial ischemia is electrical instability 
leading to ventricular tachycardia or ventricular ?brillation. 
Stress tests and coronary arteriography may also provide 
diagnostic information. These diagnostic test results may 
determine the need for deltorphin administration. 
Since ischemic heart disease is usually asymptomatic 
until the extent of coronary artery blockage is Well 
advanced, preventative measures to control risk factors and 
life style patterns associated With the disease are also 
recommended. In patients in the symptomatic phase of the 
disease, meticulous attention to life patterns or risk factors 
must be given in an attempt to promote lesion regression or 
at least prevent progression. Risk factors include a positive 
family history of ischemic heart disease, diabetes, 
hyperlipidemia, hypertension, obesity and cigarette smok 
ing. Life patterns include sedentary lifestyle, psychosocial 
tension and certain personality traits. 
Deltorphins may be administered to asymptomatic indi 
viduals having one or more risk factors and/or life style 
patterns, or to individuals already in the symptomatic phase 
of ischemic heart disease to reduce or prevent disease 
progression. Additionally, deltorphins may be administered 
to the folloWing patients: those having careers that involve 
the safety of others (e.g., commercial airline pilots) and that 
present With questionable symptoms, suspicious or positive 
noninvasive test results, and in Whom there are reasonable 
doubts about the state of the coronary arteries; males Who 
are 45 or older and females Who are 55 or older Who Will 
undergo valve replacement and Who may or may not have 
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clinical evidence of myocardial ischemia; and those at high 
risk after myocardial infarction because of the recurrence of 
angina, heart failure, frequent ventricular premature 
contractions, or signs of ischemia in the stress test, to name 
just a feW. Deltorphins may be administered either sepa 
rately or in combination With other cardiac drugs such as 
nitrates, beta-adrenergic blockers, calcium channel antago 
nists and/or aspirin and either separately or in combination 
With ?brinolytic drugs such as tissue plasminogen activator 
(tPA), streptokinase and urokinase. Use of deltorphins may 
prolong life and/or reduce or eliminate the need for invasive 
procedures such as coronary arteriography and coronary 
artery bypass grafting. 
According to the present invention, deltorphins are 
administered to a mammal to treat cerebral or spinal cord 
ischemia or ischemic heart disease. Deltorphins may be 
formulated for administration in an aqueous based liquid 
such as phosphate buffered saline to form an emulsion, or 
they may be formulated in an organic liquid such as cyclo 
dextran or dimethylsulfoxide to form a solution. The solu 
tion or emulsion may be administered by any route, but it is 
preferably administered parenterally such as by intravenous, 
intramuscular, intradermal or intraperitoneal injections. 
A preferred deltorphin dose is in the range of about 0.5 
mg/kg body Weight of the mammal to about 20 mg/kg body 
Weight, or alternatively loWer doses of about 1 pig/kg body 
Weight to about 1000 pig/kg body Weight of the mammal. 
The time of administration of a single dose of the deltorphin 
is preferably up to about four hours after onset of an 
ischemic episode. HoWever, the deltorphin may be admin 
istered concurrently With the onset of an ischemic episode or 
even prior to onset of ischemia and still produce a thera 
peutic effect. 
Ef?cacy of deltorphin treatment may be evaluated using 
noninvasive clinical imaging methods such as magnetic 
resonance imaging (MRI) of the affected region to determine 
the siZe of the damaged area. In cerebral ischemia, it is also 
possible to assess neurologic de?cit by performance on 
behavioral tests such as cognitive recognition or memory 
function such as the National Institutes of Health (NIH) 
stroke scale. 
While the speci?c mechanism of deltorphin action on 
ischemia is unknoWn, deltorphins exhibit a speci?c and 
reproducible effect on decreasing neurological de?cit and 
cerebral infarct volume. This invention Will be further 
appreciated in light of the folloWing example. 
EXAMPLE 
A murine model of ischemia/reperfusion injury Was used 
to evaluate the effects of deltorphin on cerebral blood ?oW, 
behavioral changes and ischemic infarct volume. 
Induction of Ischemia 
lschemia Was induced by transient occlusion of the exter 
nal carotid artery (ECA). Male ICR mice Weighing about 
30—35 g Were anesthetiZed With an intraperitoneal (i.p.) 
injection of chloral hydrate (350 mg/kg of body Weight) and 
xylaZine (4 mg/kg of body Weight). Rectal temperatures 
Were maintained at 37:0.5° C. With a heating pad and 
incubator. The left femoral artery Was cannulated With a 
PE-10 catheter for measurement of arterial blood pressure, 
p02, pCO2 and pH. 
A midline incision Was made in the skin of the neck and 
the left common carotid artery (LCCA) Was exposed. The 
ECA, superior thyroid artery (STA) and occipital artery 
(OA) Were isolated. The STA and OA Were electrocoagu 
lated using a cautery probe (Baxter Hi Temp Cautery, Baxter 
Healthcare Corp.) and divided. The base of the ECA Was 
secured With a microsurgical clip, then the distal end of the 
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ECA Was ligated With a 6-0 nylon suture and the ECA Was 
cut. A blunted 5-0 blue mono?lament nylon suture Was 
placed in the end of the ECA, the surgical clip Was removed, 
then the blunted suture Was advanced into the ECA until 
resistance Was detected. The blunted suture Was then tight 
ened to prevent both slipping of the internal suture and 
bleeding. The suture Was trimmed and the incision Was 
sealed by suturing the skin. The suture remained in place for 
varying lengths of time up to 24 h. At the desired time, 
reperfusion of the brain (restoration of blood How to the 
brain) Was accomplished by retreating the suture from the 
ECA. 
Mean arterial blood pressure (MABP), p02, pCO2 and pH 
Were measured before occlusion, 10 min after occlusion and 
30 min after reperfusion. Cerebral blood How Was monitored 
by laser-Doppler ?oWmetry With a ?ber optic probe placed 
2 mm posterior and 6 mm lateral to the bregma on the 
ipsilaterial hemisphere of the brain. 
Treatment 
Test compounds Were the delta opioid DADLE (Tyr-D 
Ala-Gly-Phe-D-Leu-enkephalin) and deltorphin I SEQ ID 
NO:1. For analysis of various test compounds, a solution of 
the test compound in saline or 1 % cyclodeXtran Was 
prepared. The test compound in solution Was administered 
by ip injection at multiple doses prior to or up to 4 h 
folloWing ischemic injury. 
Control animals (n=8) received i.p. injections of saline or 
1% cyclodeXtran. DADLE-treated animals (n=8) and 
deltorphin-treated animals (n=8) received 4 mg/kg of either 
DADLE or deltorphin at each of the folloWing times prior to 
ischemic injury: 6.5 h, 4.5 h, 2.5 h and 0.5 h. At time 0, 
animals Were subjected to 1 h focal middle cerebral arterial 
occlusion (MCAO) ischemia and 24 h of reperfusion. Cere 
bral blood Was assessed by laser-Doppler ?oWmetry With a 
?ber optic probe prior to ischemia and at 0.5 h, 1 h and 2 h 
post ischemia. Ischemic volume Was measured and animals 
Were assessed for behavior changes using a numerical 
ranking from 0 to 3 according to the folloWing criteria: 0=no 
observable de?cits (normal); 1 =failure to eXtend right 
forepaW upon lifting by the tail (mild); 2 =circling to the 
contralateral side (moderate); and 3=leaning to the contralat 
eral side at rest or no spontaneous motor activity (severe). 
Evaluation of Treatment 
Brain infarct volume Was measured after 1 h of ischemia 
and again at 24 h after reperfusion. At the desired endpoint, 
the animal Was euthaniZed. The brain Was immediately 
removed and placed into a mouse brain matriX (ASI, Warren, 
MI) and 2 mm sections Were made. Brain sections Were 
stained With 2% 2,3,5-triphenyltetraZolium chloride (TTC). 
Infarct siZe Was determined according to the formula: 
(contralateral volume-ipsilaterial undamaged volume)><100/con— 
tralateral volume 
to eliminate the effects of edema. Quantitation of contralat 
eral and ipsilaterial volumes Was determined by image 
analysis using a Scion Image (NIH Image Version 1.59) 
modi?ed by Scion Corp. and Adobe Photoshop 2.0.1. 
Statistical analysis of the volume analysis results Was 
performed using the Student’s t-test or analysis of variance 
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(ANOVA) folloWed by the Bonferroni test. Statistical sig 
ni?cance Was assigned to comparisons of sections from 
control versus DADLE- or deltorphin-treated animals With 
p<0.05. Data Were expressed as meanistandard error of the 
mean (SEM). 
Results 
Prior to DADLE treatment, there Were no signi?cant 
differences in MABP, p02, pCO2, pH or rectal temperature 
betWeen control animals and DADLE-treated animals. Upon 
induction of ischemia by middle cerebral arterial occlusion, 
both control and DADLE-treated animals had a 20% reduc 
tion in cerebral blood ?oW Which Was sustained for 1 h 
during the ischemia. After cessation of ischemia, cerebral 
blood ?oW returned to baseline levels Within 0.5 h. Post 
ischemia, there Were no signi?cant differences in MABP, 
p02, pCO2, pH or rectal temperature betWeen control ani 
mals and DADLE-treated animals. No changes occurred in 
neurological de?cits betWeen control animals (1.75:0.18) 
and DADLE-treated animals (1.73:0.20). Infarct volume 
Was reduced by 12% in DADLE-treated animals (67:9 
mm2) compared to control animals (76:12 mm2) after 24 h 
of reperfusion. HoWever, these differences in infarct volume 
Were not statistically signi?cant. 
Prior to deltorphin treatment, there Were no signi?cant 
differences in MABP, p02, pCO2, pH or rectal temperature 
betWeen control animals and deltorphin-treated animals. 
Upon induction of ischemia by middle cerebral arterial 
occlusion, both control and deltorphin-treated animals had a 
25% reduction in cerebral blood ?oW Which Was sustained 
for 1 h during the ischemia. After cessation of ischemia, 
cerebral blood ?oW returned to baseline levels Within 0.5 h. 
Post ischemia, there Were no signi?cant differences in 
MABP, p02, pCO2, pH or rectal temperature betWeen con 
trol animals and deltorphin-treated animals. There Was, 
hoWever, a signi?cant (p<0.05) decrease in neurological 
de?cits from deltorphin-treated animals (0.44:0.11) versus 
control animals (1.55:0.19). Additionally, infarct volume 
Was also signi?cantly reduced by 42% in deltorphin-treated 
animals (45:10 mm2) compared to control animals (73:13 
mm2) after 24 h of reperfusion. 
A method for treating cerebral or spinal cord ischemia or 
ischemic heart disease by deltorphin administration is thus 
disclosed. Deltorphins, either deltorphin I SEQ ID NO:1, 
deltorphin II SEQ ID NO:2 or a combination of deltorphins 
I SEQ ID NO:1 and II SEQ ID NO:2 are formulated for 
biocompatable administration in a preferred dose in the 
range of about 0.5—20 mg/kg, or alternatively 1—1000 pig/kg 
body Weight of the animal. The deltorphin dose may be 
administered up to four hours after the onset of an ischemic 
attack. Alternatively, the deltorphin dose may be adminis 
tered prophylactically in patients at risk for an ischemic 
attack such as, for example, prior to surgery. Deltorphin 
administration reduces the effect of an ischemic event. 
It should be understood that the embodiments of the 
present invention shoWn and described in the speci?cation 
are only preferred embodiments of the inventors Who are 
skilled in the art and thus are not limiting in any Way. 
Therefore various changes, modi?cations or alterations to 
these embodiments may be made or resorted to Without 
departing from the spirit of the invention and the scope of 
the folloWing claims. 
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SEQUENCE LISTING 
( 1) GENERAL INFORMATION: 
(iii) NUMBER OF SEQUENCES: 2 
(2) INFORMATION FOR SEQ ID NO: 1 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 7 amino acids 
(B) TYPE: amino acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: peptide 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : 
Tyr Ala Phe Asp Val Val Gly 
l 5 
(2) INFORMATION FOR SEQ ID NO: 2 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 7 amino acids 
(B) TYPE: amino acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: peptide 
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: 
Tyr Ala Phe Glu Val Val Gly 
l 5 
What is claimed is: 
1. A method of treating ischemia in a mammal experi 
encing ischemia comprising administering a deltorphin 
selected from the group consisting of deltorphin I repre 
sented by SEQ ID NO:1, deltorphin II represented by SEQ 
ID NO:2 and combinations thereof to the mammal in a 
parmaceutically acceptable formulation. 
2. The method of claim 1 Wherein 
administered prior to onset of ischemia. 
3. The method of claim 1 Wherein said deltorphin is 
administered up to four hours subsequent to onset of 
ischemia. 
4. The method of claim 1 Wherein said deltorphin is 
administered substantially concurrently With onset of 
ischemia. 
5. The method of claim 1 Wherein said deltorphin is 
administered in the formulation selected from the group 
consisting of a solution, an emulsion and a suspension. 
6. The method of claim 1 Wherein said deltorphin is 
administered parenterally. 
7. The method of claim 1 Wherein said deltorphin is 
administered at a concentration in the range of about 0.5—20 
mg/kg of body Weight of said mammal. 
8. The method of claim 1 Wherein said deltorphin is 
administered at a concentration in the range of about 1—1000 
pig/kg of body Weight of said mammal. 
9. The method of claim 1 Wherein said deltorphin is 
administered to treat cerebral ischemia. 
10. The method of claim 1 Wherein said deltorphin is 
administered to treat ischemic heart disease. 
11. The method of claim 1 Wherein said deltorphin is 
administered to treat spinal cord ischemia. 
12. A method for treating cerebral ischemia in a mammal 
experiencing ischemia comprising administering a pharma 
said deltorphin is 
35 
45 
55 
65 
ceutically effective concentration of a deltorphin selected 
from the group consisting of deltorphin I represented by 
SEQ ID NO:1, deltorohin II represented by SEQ ID NO:2 
and combinations thereof. 
13. A method for reducing effects of an ischemic episode 
in a mammal experiencing ischemia comprising administer 
ing a pharmaceutically effective concentration of a deltor 
phin selected from the group consisting of deltorphin I 
represented by SEQ ID NO:1, deltorphin II represented by 
SEQ ID NO:2 and combinations thereof. 
14. The method of claim 13 Wherein said deltorphin is 
administered up to four hour subsequent to said ischemic 
episode. 
15. The method of claim 13 Wherein said deltorphin is 
administered prior to said ischemic episode. 
16. The method of claim 13 Wherein said deltorphin is 
administered substantially concurrently With onset of 
ischemia. 
17. A method of inhibiting ischemia in a mammal at risk 
for ischemia comprising administering a deltorphin selected 
from the group consisting of deltorphin I represented by 
SEQ ID NO:1, deltorphin II represented by SEQ ID NO:2 
and combinations thereof to the mammal in a pharmaceu 
tically acceptable formulation. 
18. The method of claim 17 Wherein said deltorphin is 
administered in the formulation selected from the group 
consisting of a solution, an emulsion and a suspension. 
19. The method of claim 17 Wherein said deltorphin is 
administered parenterally. 
20. The method of claim 17 Wherein said deltorphin is 
administered at a concentration in the range of about 0.5—20 
mg/kg of body Weight of said mammal. 
21. The method of claim 17 Wherein said deltorphin is 
administered at a concentration in the range of about 1—1000 
pig/kg of body Weight of said mammal. 
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22. The method of claim 17 wherein said deltorphin is 
administered to prevent cerebral ischemia. 
23. The method of claim 17 Wherein said deltorphin is 
administered to prevent ischemic heart disease. 
24. The method of claim 17 Wherein said deltorphin is 
administered to prevent spinal cord ischemia. 
25. A method for inhibiting ischemia in a mammal at risk 
for ischemia comprising administering a pharmaceutically 
10 
effective concentration of a deltorphin selected from the 
group consisting of deltorphin I represented by SEQ ID 
NO:1, deltorphin II represented by SEQ ID NO:2 and 
combinations thereof. 
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